03/17/2026
Alzheimer’s disease remains a vast, urgent problem—about 7.2 million Americans age 65+ are living with Alzheimer’s dementia in 2025, and once diagnosed, people typically survive ~4–8 years (some longer), reflecting a progressive loss of independence and high caregiver burden. Recently approved anti-amyloid antibodies have moved the field forward but leave substantial unmet need: lecanemab slowed clinical decline by 27% on CDR-SB at 18 months in early AD, and donanemab earned FDA approval after a Phase 3 trial showing significantly slowed cognitive and functional decline (reported as ~35% in sponsor disclosures). 60xx is our investigational small-molecule program aimed at complementing these modalities by addressing upstream drivers of neurodegeneration (e.g., synaptic loss and neuroinflammatory pathways). We’re optimizing 60xx for high CNS-relevant potency and drug-like properties with a biomarker-guided strategy to enable rational combinations and patient selection—ultimately aiming to translate into slower decline and longer, higher-quality survival than today’s options. (60xx is investigational and not approved.)
